Founded in 2018 by Martin Rose and Jesper Breum, TETRAPHARM is a Copenhagen-based biopharmaceutical company focused on the development of innovative therapies in neuroscience, psychiatry, and metabolic disorders, with a strong emphasis on chronic treatment targeting underlying disease causes rather than symptoms. The company is located in Copenhagen, firmly within Medicon Valley – the leading international life science cluster spanning the Greater Copenhagen region and southern Sweden.
TETRAPHARM offers end-to-end CDMO services built around its proprietary drug delivery technology, ZYNDIKATE®, helping partners develop scalable and clinically robust pharmaceutical products. The company has 11-50 employees and reported revenue under $5 million. The company has multiple candidates in its R&D pipeline intended for obesity (with neurological focus), chronic pain, Alzheimer's and mental health disorders.
Recent Leadership News
TETRAPHARM appointed Rolf Sass Sørensen as Chief Executive Officer, effective October 6, 2026, succeeding co-founder Martin Rose, who founded the company with Jesper Breum in 2018. Sørensen brings more than 30 years of experience, including senior roles in investor relations and corporate communications, and previously served as Vice President Investor Relations & Communications at Bavarian Nordic. Founders Martin Rose and Jesper Breum move on to pursue new biotech ventures while remaining shareholders in TETRAPHARM.
Facts compiled by Executive Moves from publicly available news and press releases on 9 October 2026. Spotted an inaccuracy? Email us and we'll review within 1 business day.
To upgrade to a Premium Profile reach out to us at info@executive-moves.com.
Are you on the TETRAPHARM team?
This is a Light company page, auto-generated from public news coverage. Claim it to verify the company description, add logo and links, and control how your organisation is represented on Executive Moves.
Claim this company →
